Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip’s recent coverage of the global biopharmaceutical industry.

This new microcast provides a brief audio tour around Scrip’s Five Must-Know Things, in this episode for the week ended 26 June.

On the agenda this time are Pfizer Inc. and Sanofi’s coronavirus development plans and policies, what increased use of dexamethasone might mean for Indian pharma, Boehringer Ingelheim International GmbH’s M&A strategy, and an infographic on the state of global biopharma R&D.

Stories mentioned in this episode:

(Also see "Pfizer’s Bourla On COVID-19 Vaccine: "There Is No ROI That Will Drive Our Decision"" - Scrip, 22 Jun, 2020.)

(Also see "Sanofi Confident Of 'Tortoise And Hare' COVID-19 Vaccine Strategy" - Scrip, 23 Jun, 2020.)

(Also see "Is Dexamethasone The Next HCQ For Indian Pharma?" - Scrip, 19 Jun, 2020.)

(Also see "Boehringer’s Philosophy Of Deal-Making: A Conversation With Ioannis Sapountzis And Scott DeWire" - Scrip, 19 Jun, 2020.)

(Also see "The 2020 Worldwide Pharma & Biotech Industry R&D Scene" - Scrip, 24 Jun, 2020.)

 

 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1131690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel